demonstrated that miR-17-92 boosts CD8+ T lymphocyte migration to GVHD target organs but has little influence on CD8+ T lymphocyte proliferation, survival, or cytolytic capability, which might retain the benefits of MEXs on GVL (37). Here, CD8A is linked to graft versus host disease.